Rare Diseases
The field has solved editing efficiency. What kills programs now is causal uncertainty, a closed reversibility window, a modality matched to the wrong mechanism — and the economics of treating one private variant at a time.
From Unsolved Variant to Programmable Therapy
- DOSSIER70–90 pp · 26 figures. A convergent-node atlas and a cross-gate, cross-disease convergence map.
- WORKBOOK22 sheets. 91 claims, the node atlas, disease/variant/modality/delivery trackers.
- AUDIT~94 / 100 — our highest. Every citation re-verified live, zero retractions.
- HYPOTHESES16 falsifiable, dated, coupling two gates or two diseases.
Exactly what's inside From Unsolved Variant to Programmable Therapy.
The full research-report table of contents and every one of the 22 tables in the evidence workbook — the real structure of what you license, not a teaser.
- Executive Summary
- Scope & Evidence-Integrity Statement
- Decision Snapshot
- Buyer Decision Cheat Sheet
- Source Quality Dashboard
- The Variant-to-Rescue Causal Cascade
- 2025–2026 Current Signal Update
- Cross-Gate & Cross-Disease Convergence Map
- Evidence Maturity & Modality Matrix
- Key Findings
- Quantitative Evidence
- Key Findings & Quantitative Synthesis
- Mechanistic Deep-Dive
- Safety, Failure Modes & Reliability
- Manufacturing, CMC & Feasibility
- Non-Obvious Early Opportunities
- Prioritized Hypotheses
- Most Valuable Next Studies
- Validation / Falsification Gates
- Regulatory & Evidence-Standards Pathway
- Ethical, Access & Societal Considerations
- Commercial, Adoption & Buyer Relevance
- Strategic Recommendations
- Limitations
- Final Judgment
- Expert Review & Validation
- Appendix — Methodology, Glossary & Verification Log
- References
Workbook Guide
An orientation to the workbook — its scope, how the claim counts reconcile, and the audit posture.
In this dossier: Tier C CLIENT-FACING evidence workbook for the AI-Multi-Omics 'Unsolved Variant -> Programmable Therapy' dossier. Every citation independently re-verified (Europe PMC…
Claim Ledger
Every factual claim in the report, independently re-verified against its primary source, each carrying a support verdict and a recalibrated evidence grade.
In this dossier: All 89 customer-facing claims joined to the independently re-verified source. 'Citation quality (recalibrated)' is the from-scratch grade on intrinsic quality +…
Evidence Table
The full registry of cited sources — PMIDs, NCTs and DOIs — with metadata, resolved live against the primary record.
In this dossier: Per-source verified metadata (Europe PMC / Crossref / ClinicalTrials.gov v2) with the recalibrated citation-quality grade. 0 retractions across all resolved identifiers.
Source-Support Verdicts
The verbatim source excerpt behind each claim, with an independent verdict on whether the source actually supports it.
In this dossier: Independent per-claim support verdict with number-concordance basis: 'all-match' means every quantitative value in the claim was re-found in the freshly fetched primary…
Source Quality Summary
A reconciled view of source quality across the evidence base, with the grading rationale.
In this dossier: Recalibrated customer-facing grades shown beside the superseded internal hyper-critical screen. The internal screen was a deliberately conservative first-draft pass to…
Modality-Gate Scorecard
Programs or modalities scored on the framework's axes — a structured, side-by-side comparison (expert, ordinal, non-evidentiary).
In this dossier: Each modality scored 0-4 against the five Variant-to-Rescue gates. ORDINAL EXPERT SYNTHESIS, NON-EVIDENTIARY — a structured comparison of where each intervention clears…
Causal-Cascade-Gate Scorecard
Programs or modalities scored on the framework's axes — a structured, side-by-side comparison (expert, ordinal, non-evidentiary).
In this dossier: The five coupled gates of the Variant-to-Rescue Causal Cascade: each is necessary, none sufficient, and a program dies at the first it fails.
Disease-Variant Tracker
A structured tracker of the programs, signals and evidence in this dimension of the analysis.
In this dossier: Every named disease/gene/variant in the customer-facing set with its defect class, functional model, and reversibility status. Reversibility is single-source and…
Modality-Delivery Tracker
A structured tracker of the programs, signals and evidence in this dimension of the analysis.
In this dossier: Every editor/ASO/vector with verified efficiency, target tissue, durability, redosing, and off-target profile. The 2026 shift: redosable non-viral/EV rises as one-shot…
Asset-Sponsor Tracker
Who is developing what — assets, sponsors and platforms, with the reporting basis made explicit.
In this dossier: Named programs and sponsors with modality, stage, and the latest 2026 readout. Company- and conference-reported items are labelled and are NOT treated as independently…
Trial-Catalyst Tracker
A dated calendar of trials and readouts — sponsor, phase, indication, and the catalyst that moves the thesis.
In this dossier: Verified ClinicalTrials.gov trials and 2026 regulatory catalysts. Trial status refreshed June 2026. The plausible-mechanism framework is DRAFT guidance, not an approval.
Failure-Mode Tracker
A structured tracker of the programs, signals and evidence in this dimension of the analysis.
In this dossier: Failure modes mapped to the gate they threaten, with translation impact and mitigation. Delivery toxicity now dominates the hierarchy.
Convergent-Node Atlas
A structured table within the evidence workbook.
In this dossier: The platform thesis: distinct genes collapse onto a few shared reversible nodes with measurable readouts. Validate each node by rescue across >=3 genes (the…
Biomarker-Endpoint Map
How candidate biomarkers map to clinical endpoints — the bridge from a measurement to an outcome.
In this dossier: Biomarkers mapped to node/disease and role. Node biomarkers are the route to disease-agnostic surrogate endpoints for node-defined umbrellas.
Regulatory Tracker
Regulatory designations and pathways relevant to each program — noting that a designation is never an approval.
In this dossier: Named regulatory channels with status. The plausible-mechanism framework is DRAFT guidance open for comment, not a final pathway and not an approval. The binding…
Figure Source Map
The provenance of every figure — its underlying data and how it was produced.
In this dossier: Every figure with family, anchor, buyer question, data type, source lineage, and publishability status. 26 figures (18 deterministic + 8 generative); 18 domain-specific.
Figure Attempt Ledger
The provenance of every figure — its underlying data and how it was produced.
In this dossier: Figure render status — NONE PENDING. Backend, evidence grade, directness, and limitation note per figure.
Hypotheses Ledger
The forward-looking, falsifiable hypotheses — each with a predicted readout and an explicit disconfirming test.
In this dossier: 14 falsifiable, current, cross-gate/cross-disease hypotheses. Each couples >=2 gates or >=2 diseases, predicts a 2026-2028 readout, and carries a quantified endpoint +…
Most Valuable Next Studies
The highest-leverage experiments to run next, prioritized — a ready-made research agenda.
In this dossier: Eight de-risking experiments, each clearing a specific gate. Study 1 (node atlas) is the platform-defining bet. Cost tiers are ordinal planning estimates.
Verification & Search Log
A dated log of the verification searches run — the audit trail behind the evidence.
In this dossier: Independent citation re-assessment + fresh latest-development search + recovery, with databases and counts. No claim of systematic-review completeness; a structured…
Excluded Claims
Every claim we considered and removed, with the reason — showing the work, including what didn't make the cut.
In this dossier: All 128 excluded claims with disposition. 21 capacity-dropped (excluded for volume, not relevance) are prime recoveries; off-topic items with adjacent cross-disease…
Salvage Ledger
Claims recovered from the excluded set after deeper verification.
In this dossier: Reuse / improve / replace / re-position decisions versus the accepted source report. The thesis was good; the job was to sharpen it into a decision rule, rebuild the…
Click any table to see what it is.
Different buyers live in different tabs.
Click a buyer to see exactly what they get.
Every claim resolves to a primary source.
This dossier ships with its independent diligence audit. Evidence is labelled Established / Inferred / Hypothesis. A surrogate is never equated with outcome; a designation is never an approval.
Zemi Research publishes independent, pre-packaged research reports delivered as digital downloads (PDF + spreadsheet). These are information products — not medical, clinical, investment, legal, or professional advice; not a consulting, advisory, or regulated service; and they create no professional-client relationship. Provided for general informational use by industry professionals.